A5059168662- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Urinary Bladder and Prostate Research
- Urinary Tract Infections Management
- Radiopharmaceutical Chemistry and Applications
- Urologic and reproductive health conditions
- Ureteral procedures and complications
- Esophageal Cancer Research and Treatment
- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Urological Disorders and Treatments
- Pelvic floor disorders treatments
- Renal Diseases and Glomerulopathies
- Cancer, Lipids, and Metabolism
- Urinary and Genital Oncology Studies
Kyoto University
2021-2024
Otsu Red Cross Hospital
2023-2024
Kitano Hospital
2020-2021
Introduction A ureteral stricture often develops after a cutaneous ureterostomy and can lead to complicated situations in some cases. Case presentation We performed surgery on 54‐year‐old man who required routine replacement of stent every 2 weeks cystectomy. surgically converted his into new ileal conduit. Following the surgery, was removed, allowing him resume social activities. Conclusion reported possibility urinary rediversion as treatment option for patient.
Abstract Aim To assess real‐world treatment profiles, including the time to and reasons for discontinuation or drug switching, reinitiation, postdiscontinuation follow‐up in patients receiving antimuscarinics ß3‐agonists overactive bladder (OAB) through a retrospective chart review. Methods We retrospectively reviewed medical charts of 777 patients, aged ≥18 years, who underwent antimuscarinic ß3‐agonist therapy at our hospital. Data on patient's age, sex, chief complaint, OAB symptom score...
Abstract Background The benefits of pembrolizumab in patients with advanced urothelial carcinoma (UC) and impaired performance status (PS) remain unknown. This study assessed the safety efficacy platinum‐refractory UC Eastern Cooperative Oncology Group PS ≥2 to identify which subgroups may benefit from this drug. Methods retrospective nationwide cohort collected clinicopathological information for 755 59 institutions. overall response rate (ORR) survival (OS) were compared among 0–1, 2, 3–4....
Objectives To investigate the impact of number cycles and objective response to chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated pembrolizumab. Methods This multicenter, retrospective study included 755 from 59 institutions advanced, chemoresistant who received The associations best were investigated using Cox multiple regression analysis. Results Overall, 391 standard first‐line pembrolizumab as a second‐line treatment, final Of patients, 185 less...
This retrospective observational study explored the therapeutic potential of combined androgen blockade (CAB) with bicalutamide (Bic-CAB) as an initial treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in Japan.
Objective To assess the efficacy of combination prostate‐targeted treatment and metastasis‐directed therapy for oligometastatic prostate cancer. Methods We retrospectively evaluated clinical outcomes synchronously diagnosed cancer patients treated with external beam radiation all metastatic lesions (≤3 lesions) at Kyoto University Hospital between January 2004 April 2019. The prescribed dose was basically ≥70 Gy or without whole pelvic irradiation, ≥45 lesions. Clinical were compared a...
The treatment and prognosis of de novo metastatic hormone-sensitive prostate cancer (mHSPC) vary. We established validated a novel prognostic model for predicting cancer-specific survival (CSS) in patients with mHSPC using retrospective data from contemporary cohort.
Introduction Antiphospholipid syndrome is an autoimmune disease that presents with thrombus hyperplasia. Although very rare, this reported to become severe after the surgical invasion and other interventions. To our knowledge, there are no reports of partial nephrectomy in patients antiphospholipid. Case presentation A 45‐year‐old man visited hospital for treatment left renal cell carcinoma. He had a history antiphospholipid took two antithrombotic agents. We performed robot‐assisted...